ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 626.9 | 595.5 | 303.9 |
| Other income | 14.5 | 31.4 | 22.7 |
| Total income | 641.4 | 626.9 | 326.6 |
| Profit before exceptional items & tax | 78.4 | 94.2 | 5.8 |
| Profit before tax | 78.4 | 94.2 | 5.8 |
| Net profit | 59.3 | 68.8 | 4.7 |
| Operating margin | 12.2% | 15.0% | 1.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1161.70% |
|---|---|
| Net profit, quarter on quarter | -13.80% |
| Revenue, year on year | +106.30% |
| Operating profit, year on year | +348.90% |
| Operating profit, quarter on quarter | +19.80% |
BSE results filing, NSE: TRUALT. Figures extracted from the filing.
TruAlt Bioenergy Ltd: key numbers
- Share price
- ₹350.00
- Market cap
- ₹3,001 Cr
- Revenue (annual)
- ₹1,728 Cr
- Net profit (annual)
- ₹95.95 Cr
- P/E (TTM)
- 13.6×Sector 29.0×
- Promoter holding
- 71.38%+0.83% QoQ
- FII holding
- 0.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TruAlt Bioenergy Ltd
All →TruAlt Bioenergy Other Announcement
TruAlt Bioenergy filed Crisil's monitoring agency report for the quarter ended 30 September 2026 on its Rs 750 crore IPO proceeds. The report notes no deviation from the IPO objects.
TruAlt Bioenergy Earnings Call Transcript: Key Takeaways
TruAlt reported massive 606% YoY revenue growth, turning profitable despite raw material price surges. Management is pivoting from ethanol to high-margin CBG to insulate from feedstock volatility.
TruAlt Bioenergy Investor Presentation: Key Takeaways
Q2 FY27 consolidated total income ₹823.74 Cr, PAT ₹34.99 Cr, EBITDA margin 12.47%. H1 PAT ₹94.27 Cr, EBITDA ₹233.92 Cr (16.27% margin). Strategy: integrated bioenergy across ethanol, CBG, SAF, retail.
TruAlt Bioenergy Results Update
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, EBITDA of ₹233.92 crore and PAT of ₹94.27 crore via press release. Results reverse last year's H1 loss.
TruAlt Bioenergy Q2 FY27 Results: Turns Profitable, Net Profit ₹35 Cr
TruAlt Bioenergy Ltd reported revenue from operations of ₹811.1 Cr (+605.9% YoY) and net profit of ₹35 Cr for Q2 FY27.
- Key figure
- Net profit ₹35 Cr
TruAlt Bioenergy Management Change
Mr. Monu Kumar resigned as Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, effective October 16, 2026, due to personal reasons.